Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/14/19 → 1/29/21 |
Funding
- Vertex Pharmaceuticals Inc: $48,574.00
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
- Pancham, Krishna (PI)
- Anstead, Michael (CoI)